Combination approaches that include PI3K pathway inhibitors such as everolimus [32], buparlisib [33], or alpelisib [13,34,35] have shown promising results also in breast cancer patients, and additional preclinical data also confirm the combination potential for AKT inhibitors [36]. This evidence concerns the gene AKT1 and breast cancer.